# PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

> **NCT03218826** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Advanced Breast Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Prostate Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Castration-Resistant Prostate Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Prostate Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
- Triple-Negative Breast Carcinoma
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** PI3Kbeta Inhibitor AZD8186

## Key facts

- **NCT ID:** NCT03218826
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-24
- **Primary completion:** 2022-07-25
- **Final completion:** 2025-10-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218826, "PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03218826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*